OncoCyte’s (NASDAQ:OCX) Innovative Approach: Potential in Precision DiagnosticsChronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For organ transplant patients, the risk of graft rejection remains a persistent threat, necessitating continuous monitoring to ensure long-term success. Similarly, the complexity of cancer requires advanced diagnostics to tailor treatments to individual patients, optimizing therapeutic efficacy while minimizing adverse effects.
OncoCyte's Innovative Approach: Potential in Precision DiagnosticsChronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For organ transplant patients, the risk of graft rejection remains a persistent threat, necessitating continuous monitoring to ensure long-term success. Similarly, the complexity of cancer requires advanced diagnostics to tailor treatments to individual patients, optimizing therapeutic efficacy while minimizing adverse effects.
3 Penny Stocks That Insiders Are BuyingPenny stocks are a risky business but following the insiders to your next trade can alleviate some of the risks; these are the three hottest insider buys.
Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months EarlierInterventional study compares VitaGraft to current transplant rejection monitoring protocols
Oncocyte Reports Second Quarter 2023 Financial ResultsConference Call on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET
Oncocyte Regains Compliance With Nasdaq Listing RequirementsIRVINE, CA / ACCESSWIRE / August 9, 2023 / Oncocyte Corporation (
NASDAQOCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed.
Oncocyte To Announce Second Quarter 2023 Financial ResultsConference Call and Webcast on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET
EchelonDx and Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical Test Offerings
Echelon Diagnostics, Inc., a leading provider of genomic healthcare AI imaging and big data solutions, today announced a strategic collaboration with Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum. The two companies will work together to develop analytical software that can scale to support the commercial expansion of Oncocyte’s tests and solutions that may help diagnosis and treatment of cancer, leading to improved patient outcomes and reducing the overall cost of care.
